ClinicalTrials.gg
CompletedNCT01144364Updated Aug 15, 2017Results posted

A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

A Phase 3 interventional study of rituximab [Mabthera/Rituxan] in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 45 sites in Italy. Open to participants aged 60 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 4 months after the study started (first participant enrolled Jan 2004, registered Jun 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
234
Allocation
Not applicable
Ages
60 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
22nd of 171
234 · median 38
Started
2004
with 10 others
Phase 3
29 of 178
none open now
Registered
115th of 178
by date
Lead sponsor
13 of 178
Hoffmann-La Roche

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 22nd largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2004, is one of 29 in phase 3, and was the 115th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 60 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients 60-75 years of age;
  • B-cell follicular NHL;
  • no previous treatment;
  • active disease, with rapid progression.

Exclusion criteria

Exclusion Criteria:

  • other cancer within 3 years of study, except carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ of the breast treated with lumpectomy;
  • long-term use (>1 month) of systemic ;
  • central nervous system involvement;
  • history of significant cardiovascular disease;
  • positive test result for , or or C.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    1

    Drug: rituximab [Mabthera/Rituxan]

Interventions

  • Drugrituximab [Mabthera/Rituxan]

    Drug page: Rituximab

    Intravenous repeating dose

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease Progression or Death

    PFS from randomization was measured from the date of randomization to the date of documented disease progression, relapse, or death from any cause. PFS function was estimated using Kaplan-Meier product-limit method. Responding participants and participants who were lost to follow up were censored at their last assessment date.

    Time frame: 12, 24, and 34 months

  2. PFS Randomization- Percentage of Participants Estimated to be Free of Progression at 12, 24, and 34 Months

    PFS from randomization was measured from the date of randomization to the date of documented disease progression, relapse, or death from any cause. Responding participants and participants who were lost to follow-up were censored at their last assessment date. PFS was estimated using Kaplan-Meier methods.

    Time frame: 12, 24, and 34 months

Secondary outcomes

  1. Percentage of Participants Estimated to be Free of Progression at 12, 24, and 36 Months

    PFS from enrollment was measured from the date of enrollment to the date of disease progression, relapse, or death from any cause. Responding participants and participants who were lost to follow-up were censored at their last assessment date. Estimates of PFS function were made with the Kaplan-Meier product-limit method.

    Time frame: 12, 24, and 36 months

  2. Disease-Free Survival (DFS) From Randomization - Percentage of Participants Disease Free at 12, 24, and 36 Months

    DFS was defined for all participants who achieved a complete response (CR) or unconfirmed CR (CRu) at Month 3 or later, after the completion of induction phase and was measured from the time of randomization to the date of relapse or death as a result of lymphoma or acute toxicity of treatment. Participants without relapse were censored at their last assessment date. Estimates of DFS were made using Kaplan-Meier product-limit method.

    Time frame: 12, 24, and 36 months

  3. Overall Survival (OS) From Randomization - Percentage of Participants Estimated to be Alive at 12, 24, and 34 Months

    OS from randomization was defined as the date of randomization to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.

    Time frame: 12, 24, and 34 months

  4. Overall Survival (OS) From Randomization - Percentage of Participants With Death

    OS from randomization was defined as the date of randomization to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.

    Time frame: 12, 24, and 34 months

  5. OS From Enrollment - Percentage of Participants Estimated to be Alive at 12, 24, and 36 Months

    OS from enrollment was defined as the date of enrollment to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.

    Time frame: 12, 24, and 36 months

  6. Percentage of Participants With a Response During the Induction Phase

    Participants without a response assessment (due to any reasons) were considered as non-responders.

    Time frame: Months 1 to 8

  7. Percentage of Participants With a Molecular Response in the Induction Phase

    Molecular responders were defined as the proportion of CR/CRu participants with a positive bcl-2/IgH (non-Hodgkin's Lymphoma \[NHL\] marker) at baseline, whose laboratory values were undetectable after treatment.

    Time frame: Months 5 and 8

  8. Duration of Response Using a Traditional Approach - Percentage of Participants Estimated to Have a Sustained Response at 12, 24, and 34 Months

    Duration of response (DOR) was defined for all participants who achieved a response (CR, CRu, and PR) at Month 3 or later, after the completion of induction phase and was measured from the date of randomization until the date of progression, relapse, or death as a result of follicular lymphoma (FL). Participants without relapse, progression, or death for causes other than FL were censored at their last assessment date. Analyses on this endpoint were performed with two different approaches. For the traditional approach, duration of response was estimated as the proportion of participants alive without progression or relapse of disease with the Kaplan-Meier method.

    Time frame: Months 12, 24, and 34

  9. Duration of Response Using the Competing Risk Approach - Cumulative Percentage of Participants With Progression, Relapse or Death as a Result of FL at 12, 24, and 34 Months

    DOR was defined for all participants who achieved a response (CR, CRu, and PR) at Month 3 or later, after the completion of induction phase and was measured from the date of randomization until the date of progression, relapse, or death as a result of FL. Participants without relapse, progression, or death for causes other than FL were censored at their last assessment date. Analyses on this endpoint were performed with two different approaches. For the competing risk approach, deaths for causes other than FL were considered as competing events. DOR was estimated with the cumulative incidence of progression, relapse, or death as a result of FL.

    Time frame: Months 12, 24, and 34

07

Results

Posted Dec 4, 2014

Participant flow

Induction Phase
Participant flow — Induction Phase
MilestoneInduction Phase-Immunochemotherapy Rituximab-FND (R-FND)Rituximab Induction, Rituximab MaintenanceRituximab Induction, Observation Maintenance
Started23400
Completed20200
Not completed3200
Withdrew: Disease progression1400
Withdrew: Adverse event900
Withdrew: Death100
Withdrew: Withdrawal by subject100
Withdrew: Lost to follow-up200
Withdrew: Physician decision100
Withdrew: Stable disease200
Withdrew: Secondary neoplasia100
Withdrew: Protocol violation100
Follow-Up/Maintenance Phase
Participant flow — Follow-Up/Maintenance Phase
MilestoneInduction Phase-Immunochemotherapy Rituximab-FND (R-FND)Rituximab Induction, Rituximab MaintenanceRituximab Induction, Observation Maintenance
Started0101101
Completed06660
Not completed03541
Withdrew: Disease progression02329
Withdrew: Adverse event031
Withdrew: Death020
Withdrew: Withdrawal by subject011
Withdrew: Lost to follow-up014
Withdrew: Relapse055
Withdrew: Physician decision001

Outcome measures

PrimaryPercentage of Participants With Disease Progression or Death

PFS from randomization was measured from the date of randomization to the date of documented disease progression, relapse, or death from any cause. PFS function was estimated using Kaplan-Meier product-limit method. Responding participants and participants who were lost to follow up were censored at their last assessment date.

Time frame:
12, 24, and 34 months
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression or Death
percentage of participantsRituximab Induction, Rituximab MaintenanceRituximab Induction, Observation Maintenance
Percentage of Participants With Disease Progression or Death29.734.7
Statistical analysis
  • Rituximab Induction, Rituximab Maintenance vs Rituximab Induction, Observation Maintenance · Log Rank · p = 0.254
SecondaryPercentage of Participants Estimated to be Free of Progression at 12, 24, and 36 Months

PFS from enrollment was measured from the date of enrollment to the date of disease progression, relapse, or death from any cause. Responding participants and participants who were lost to follow-up were censored at their last assessment date. Estimates of PFS function were made with the Kaplan-Meier product-limit method.

Time frame:
12, 24, and 36 months
Reported as:
Number · percentage of participants
Percentage of Participants Estimated to be Free of Progression at 12, 24, and 36 Months
percentage of participantsRituximab Induction
12 months90.1 (85.5 to 93.3)
24 months77.8 (71.8 to 82.6)
36 months65.7 (59.2 to 71.5)
SecondaryDisease-Free Survival (DFS) From Randomization - Percentage of Participants Disease Free at 12, 24, and 36 Months

DFS was defined for all participants who achieved a complete response (CR) or unconfirmed CR (CRu) at Month 3 or later, after the completion of induction phase and was measured from the time of randomization to the date of relapse or death as a result of lymphoma or acute toxicity of treatment. Participants without relapse were censored at their last assessment date. Estimates of DFS were made using Kaplan-Meier product-limit method.

Time frame:
12, 24, and 36 months
Reported as:
Number · percentage of participants
Disease-Free Survival (DFS) From Randomization - Percentage of Participants Disease Free at 12, 24, and 36 Months
percentage of participantsRituximab Induction, Rituximab MaintenanceRituximab Induction, Observation Maintenance
12 months93.0 (85.8 to 96.6)82.5 (73.4 to 88.8)
24 months82.7 (73.7 to 88.9)68.9 (58.7 to 77.2)
36 months69.2 (57.9 to 78.1)62.3 (51.2 to 71.5)
Statistical analysis
  • Rituximab Induction, Rituximab Maintenance vs Rituximab Induction, Observation Maintenance · Cox proportional-hazards · p = 0.105 (Overall DFS) · Hazard ratio (hr): 0.58 · 95% CI 0.31 to 1.12Adjusted for randomization stratum and the known prognostic factors.
SecondaryOverall Survival (OS) From Randomization - Percentage of Participants Estimated to be Alive at 12, 24, and 34 Months

OS from randomization was defined as the date of randomization to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.

Time frame:
12, 24, and 34 months
Reported as:
Number · percentage of participants
Overall Survival (OS) From Randomization - Percentage of Participants Estimated to be Alive at 12, 24, and 34 Months
percentage of participantsRituximab Induction, Rituximab MaintenanceRituximab Induction, Observation Maintenance
12 months97.0 (91.0 to 99.0)100 (NA to NA)
24 months96.0 (89.7 to 98.5)96.9 (90.6 to 99.0)
34 months96.0 (89.7 to 98.5)95.8 (89.2 to 98.4)
Statistical analysis
  • Rituximab Induction, Rituximab Maintenance vs Rituximab Induction, Observation Maintenance · Log Rank · p = 0.751
SecondaryOverall Survival (OS) From Randomization - Percentage of Participants With Death

OS from randomization was defined as the date of randomization to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.

Time frame:
12, 24, and 34 months
Reported as:
Number · percentage of participants
Overall Survival (OS) From Randomization - Percentage of Participants With Death
percentage of participantsRituximab Induction, Rituximab MaintenanceRituximab Induction, Observation Maintenance
Overall Survival (OS) From Randomization - Percentage of Participants With Death5.04.0
Statistical analysis
  • Rituximab Induction, Rituximab Maintenance vs Rituximab Induction, Observation Maintenance · Log Rank · p = 0.751
SecondaryOS From Enrollment - Percentage of Participants Estimated to be Alive at 12, 24, and 36 Months

OS from enrollment was defined as the date of enrollment to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.

Time frame:
12, 24, and 36 months
Reported as:
Number · percentage of participants
OS From Enrollment - Percentage of Participants Estimated to be Alive at 12, 24, and 36 Months
percentage of participantsRituximab Induction, Rituximab Maintenance
12 months94.9 (91.1 to 97.0)
24 months92.7 (88.4 to 95.4)
36 months89.5 (84.8 to 92.9)
PrimaryPFS Randomization- Percentage of Participants Estimated to be Free of Progression at 12, 24, and 34 Months

PFS from randomization was measured from the date of randomization to the date of documented disease progression, relapse, or death from any cause. Responding participants and participants who were lost to follow-up were censored at their last assessment date. PFS was estimated using Kaplan-Meier methods.

Time frame:
12, 24, and 34 months
Reported as:
Number · percentage of participants
PFS Randomization- Percentage of Participants Estimated to be Free of Progression at 12, 24, and 34 Months
percentage of participantsRituximab Induction, Rituximab MaintenanceRituximab Induction, Observation Maintenance
12 months92.0 (84.7 to 95.9)82.5 (73.4 to 88.8)
24 months81.0 (71.8 to 87.4)68.9 (58.7 to 77.2)
34 months70.4 (60.2 to 78.4)62.3 (51.2 to 71.5)
Statistical analysis
  • Rituximab Induction, Rituximab Maintenance vs Rituximab Induction, Observation Maintenance · Cox proportional-hazards · p = 0.079 · Hazard ratio (hr): 0.63 · 95% CI 0.38 to 1.05
SecondaryPercentage of Participants With a Response During the Induction Phase

Participants without a response assessment (due to any reasons) were considered as non-responders.

Time frame:
Months 1 to 8
Reported as:
Number · percentage of participants
Percentage of Participants With a Response During the Induction Phase
percentage of participantsRituximab Induction, Rituximab MaintenanceRituximab Induction, Observation Maintenance
Complete remission (CR/CRu)79.279.2
Partial remission19.819.8
Stable disease1.00.0
Progression disease0.00.0
Missing0.01.0
SecondaryPercentage of Participants With a Molecular Response in the Induction Phase

Molecular responders were defined as the proportion of CR/CRu participants with a positive bcl-2/IgH (non-Hodgkin's Lymphoma \[NHL\] marker) at baseline, whose laboratory values were undetectable after treatment.

Time frame:
Months 5 and 8
Reported as:
Number · percentage of participants
Percentage of Participants With a Molecular Response in the Induction Phase
percentage of participantsRituximab Induction, Rituximab Maintenance
Month 536.4
Month 858.5
SecondaryDuration of Response Using a Traditional Approach - Percentage of Participants Estimated to Have a Sustained Response at 12, 24, and 34 Months

Duration of response (DOR) was defined for all participants who achieved a response (CR, CRu, and PR) at Month 3 or later, after the completion of induction phase and was measured from the date of randomization until the date of progression, relapse, or death as a result of follicular lymphoma (FL). Participants without relapse, progression, or death for causes other than FL were censored at their last assessment date. Analyses on this endpoint were performed with two different approaches. For the traditional approach, duration of response was estimated as the proportion of participants alive without progression or relapse of disease with the Kaplan-Meier method.

Time frame:
Months 12, 24, and 34
Reported as:
Number · percentage of participants
Duration of Response Using a Traditional Approach - Percentage of Participants Estimated to Have a Sustained Response at 12, 24, and 34 Months
percentage of participantsRituximab Induction, Rituximab MaintenanceRituximab Induction, Observation Maintenance
12 Months93.9 (86.9 to 97.2)82.3 (73.1 to 88.6)
24 Months83.6 (74.6 to 89.6)68.6 (58.3 to 76.9)
34 Months69.9 (58.5 to 78.7)61.9 (50.9 to 71.2)
Statistical analysis
  • Rituximab Induction, Rituximab Maintenance vs Rituximab Induction, Observation Maintenance · Regression, Cox · p = 0.103 (Univariate analysis) · Hazard ratio (hr): 0.66 · 95% CI 0.40 to 1.09Cox model stratified for the stratification groups.
  • Rituximab Induction, Rituximab Maintenance vs Rituximab Induction, Observation Maintenance · Regression, Cox · p = 0.071 (Multivariate analysis) · Hazard ratio (hr): 0.62 · 95% CI 0.37 to 1.04Adjusted for stratification group, age, sex, Eastern Cooperative Oncology Group Performance Status, FL International prognostic index (FLIPI) score.
SecondaryDuration of Response Using the Competing Risk Approach - Cumulative Percentage of Participants With Progression, Relapse or Death as a Result of FL at 12, 24, and 34 Months

DOR was defined for all participants who achieved a response (CR, CRu, and PR) at Month 3 or later, after the completion of induction phase and was measured from the date of randomization until the date of progression, relapse, or death as a result of FL. Participants without relapse, progression, or death for causes other than FL were censored at their last assessment date. Analyses on this endpoint were performed with two different approaches. For the competing risk approach, deaths for causes other than FL were considered as competing events. DOR was estimated with the cumulative incidence of progression, relapse, or death as a result of FL.

Time frame:
Months 12, 24, and 34
Reported as:
Number · percentage of participants
Duration of Response Using the Competing Risk Approach - Cumulative Percentage of Participants With Progression, Relapse or Death as a Result of FL at 12, 24, and 34 Months
percentage of participantsRituximab Induction, Rituximab MaintenanceRituximab Induction, Observation Maintenance
12 Months6.1 (1.3 to 10.8)17.7 (10.0 to 25.3)
24 Months16.2 (8.9 to 23.5)31.4 (22.0 to 40.8)
34 Months29.5 (19.5 to 39.6)38.0 (27.8 to 48.3)
Statistical analysis
  • Rituximab Induction, Rituximab Maintenance vs Rituximab Induction, Observation Maintenance · Fine and Gray model · p = 0.084 (Univariate analysis) · Hazard ratio (hr): 0.65 · 95% CI 0.39 to 1.06Fine and Gray model stratified for the stratification groups.
  • Rituximab Induction, Rituximab Maintenance vs Rituximab Induction, Observation Maintenance · Fine and Gray model · p = 0.052 · Hazard ratio (hr): 0.62 · 95% CI 0.38 to 1.00Fine and Gray model adjusted for stratification group, age, sex, Eastern Cooperative Oncology Group Performance Status, and FLIPI score

Adverse events

Collected over Adverse events (AEs) were reported up to Month 15.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab Induction (Induction Phase Only)—19/233 (8.2%)230/233 (98.7%)
Rituximab Induction, Rituximab Maintenance (Follow-up Phase)—19/101 (18.8%)73/101 (72.3%)
Rituximab Induction, Observation Maintenance (Follow-up Phase)—17/101 (16.8%)55/101 (54.5%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventRituximab Induction (Induction Phase Only)Rituximab Induction, Rituximab Maintenance (Follow-up Phase)Rituximab Induction, Observation Maintenance (Follow-up Phase)
CholelithiasisGastrointestinal disorders0/2330/1013/101
Hepatitis BInfections and infestations1/2331/1012/101
Myocardial infarctionCardiac disorders0/2332/1010/101
PneumoniaInfections and infestations0/2332/1012/101
Angina pectorisCardiac disorders0/2330/1012/101
PyrexiaImmune system disorders2/2330/1011/101
Abdominal painGastrointestinal disorders1/2331/1010/101
NeutropeniaBlood and lymphatic system disorders0/2331/1010/101
Cardiac ablationCardiac disorders0/2331/1010/101
Wolff-Parkinson-White syndromeCardiac disorders0/2331/1010/101
Most frequent other events
Showing 10 of 269
Most frequent other events
EventRituximab Induction (Induction Phase Only)Rituximab Induction, Rituximab Maintenance (Follow-up Phase)Rituximab Induction, Observation Maintenance (Follow-up Phase)
NeutropeniaBlood and lymphatic system disorders225/23316/1012/101
ThrombocytopeniaBlood and lymphatic system disorders120/2332/1011/101
AnaemiaBlood and lymphatic system disorders103/2331/1011/101
Asthenia/fatigueGeneral disorders57/2330/1010/101
PyrexiaGeneral disorders44/2338/1013/101
NauseaGastrointestinal disorders43/2330/1010/101
PainGeneral disorders31/2330/10113/101
CoughRespiratory, thoracic and mediastinal disorders17/23313/10110/101
ConstipationGastrointestinal disorders24/2331/1011/101
DiarrhoeaGastrointestinal disorders23/2332/1011/101

Baseline characteristics

Intention-to-Treat (ITT) population: all participants who were randomized to the maintenance or observation arm. IP population: all enrolled participants who started the induction phase (Months 1-8 of the study)

Age, Continuous
Age, Continuous(years)Rituximab Induction, Rituximab MaintenanceRituximab Induction, Observation MaintenanceTotal
Median66 (64 to 70)65 (62 to 69)66 (63 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab Induction, Rituximab MaintenanceRituximab Induction, Observation MaintenanceTotal
Female6456120
Male374582
08

Study locations

45 sites
  • Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia
    Pescara, Abruzzo 65100, Italy
  • Ospedale Riuniti; Divisione Di Ematologia
    Reggio Calabria, Calabria 89100, Italy
  • Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica
    Napoli, Campania 80131, Italy
  • Nuovo Policlinico, Ii Facolta; Divisione Di Ematologia
    Napoli, Campania 80131, Italy
  • Ospedale Cardarelli; Divisione Di Ematologia
    Napoli, Campania 80131, Italy
  • Presidio Ospedaliero Umberto I; U.O. Di Medicina Interna Ed Oncoematologia
    Nocera Inferiore, Campania 84014, Italy
  • A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
    Bologna, Emilia-Romagna 40138, Italy
  • A.O. Universitaria Policlinico Di Modena; Ematologia
    Modena, Emilia-Romagna 41100, Italy
  • A.O. Universitaria Policlinico Di Modena; Radiologia
    Modena, Emilia-Romagna 41100, Italy
  • Az. Osp. Ospedale Civile; U.O. Di Oncologia Medica Ed Ematologia
    Piacenza, Emilia-Romagna 29100, Italy
  • Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia
    Ravenna, Emilia-Romagna 48100, Italy
  • Az. Osp. Arcispedale S. Maria Nuova; U.O. Di Ematologia
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • Policlinico Universitario; Clinica Oncologia - Padiglione Pennato
    Udine, Friuli-Venezia Giulia 33100, Italy
  • Ospedale S. Eugenio; Divisione Di Ematologia
    Roma, Lazio 00144, Italy
  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia;Dip. Biotecnologie Cel CELLULARI ED EMATOLOGIA
    Roma, Lazio 00161, Italy
  • Uni Cattolica; Divisione Di Ematologia
    Roma, Lazio 00168, Italy
  • ASST PAPA GIOVANNI XXIII; Ematologia
    Bergamo, Lombardia 24127, Italy
  • A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia
    Brescia, Lombardia 25123, Italy
  • ASST DI CREMONA; U.O.S. di Ematologia
    Cremona, Lombardia 26100, Italy
  • Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora
    Milano, Lombardia 20122, Italy
  • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
    Milano, Lombardia 20133, Italy
  • Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico
    Milano, Lombardia 20133, Italy
  • Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
    Milano, Lombardia 20162, Italy
  • ASST DI MONZA; Ematologia
    Monza, Lombardia 20052, Italy
  • Ospedale Regionale Di Torrette; Clinica Di Ematologia
    Ancona, Marche 60020, Italy
  • Ospedale Civile; S.C. Ematologia
    Pesaro, Marche 61100, Italy
  • Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia
    Alessandria, Piemonte 15121, Italy
  • Az. Osp. Di Biella; Divisione Di Ematologia
    Biella, Piemonte 13051, Italy
  • Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico
    Candiolo, Piemonte 10060, Italy
  • Az. Osp. S. Croce Ospedale Generale; Sezione Di Ematologia
    Cuneo, Piemonte 12100, Italy
  • Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico
    Orbassano, Piemonte 10043, Italy
  • A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1
    Torino, Piemonte 10126, Italy
  • A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia
    Torino, Piemonte 10126, Italy
  • Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica
    Bari, Puglia 70124, Italy
  • IRCCS Ospedale Casa Sollievo Della Sofferenza; Ematologia E Trapianto Di Midollo Osseo
    San Giovanni Rotondo, Puglia 71013, Italy
  • Ospedale Oncologico A Businco-Cagliari; Ematologia Sez.
    Cagliari, Sardegna 09121, Italy
  • Az. Osp. Papardo; Struttura Complessa Di Ematologia
    Messina, Sicilia 98165, Italy
  • Ospedale V. Cervello; U.O. Ematologia E Trapianti
    Palermo, Sicilia 90146, Italy
  • Ospedale Ferrarotto; Divisione Di Ematologia
    Via S. Sofia 78, Sicilia 95123, Italy
  • Az. Osp. Di Careggi; Divisione Di Ematologia
    Firenze, Toscana 50135, Italy
  • Ospedale Santa Chiara; Unita Operativa Di Ematologia
    Pisa, Toscana 56100, Italy
  • Azienda Sanitaria Di Bolzano; Ematologia E Centro Trapianto Mid.Osseo
    Bolzano, Trentino-Alto Adige 39100, Italy
  • Dept. Medicina Clinica E Sperimentale; Sez. Medicina Interna E Scienze Oncologiche - Pol. Monteluce
    Perugia, Umbria 06126, Italy
  • Ospedale Civile Ss. Giovanni E Paolo; Ematologia
    Venezia, Veneto 30122, Italy
  • Uni Di Verona Policlinico G.B. Rossi; Divisione E Cattedra Di Ematologia
    Verona, Veneto 37130, Italy
09

References and documents

Publications

  • Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. PubMed 24085766 ↗
  • Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, Pinto A, De Renzo A, Zaja F, Castellino C, Bari A, Alvarez De Celis I, Evangelista A, Parvis G, Gamba E, Lobetti-Bodoni C, Ciccone G, Rossi G. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Sep 20;31(27):3351-9. doi: 10.1200/JCO.2012.44.8290. Epub 2013 Aug 19. PubMed 23960180 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2004 to primary completion in Jul 2011, 90 months.

Results were first posted in Dec 2014, 3 years 4 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 90 months is above that.

Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2010
First posted
Jun 15, 2010
StartActual
Jan 19, 2004
Primary completionActual
Jul 21, 2011
CompletionActual
Jul 21, 2011
Results first posted
Dec 4, 2014
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01144364
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 15, 2010
Start date
Jan 19, 2004
Primary completion
Jul 21, 2011
Completion
Jul 21, 2011
Results posted
Dec 4, 2014
Last update
Aug 15, 2017

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion